Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative C. Scott Franklin (Republican-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 17th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on August 26th. The trade occurred in the Representative’s “FIDELITY ROTH IRA” account.

Representative C. Scott Franklin also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 8/26/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 8/20/2026.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 8/20/2026.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 8/20/2026.

Novo Nordisk A/S Price Performance

NVO stock opened at $43.23 on Friday. The firm has a market cap of $193.04 billion, a P/E ratio of 10.57, a P/E/G ratio of 1.42 and a beta of 0.74. The firm’s fifty day moving average is $46.84 and its 200 day moving average is $43.81. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. Research analysts predict that Novo Nordisk A/S will post 3.53 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were issued a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 20.05%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NVO. CoreCap Advisors LLC lifted its holdings in Novo Nordisk A/S by 4.7% in the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after buying an additional 242 shares during the period. Carson Advisory Inc. increased its stake in shares of Novo Nordisk A/S by 2.2% during the first quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock valued at $453,000 after buying an additional 268 shares during the period. Bradley Foster & Sargent Inc. CT raised its holdings in shares of Novo Nordisk A/S by 0.6% during the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock valued at $1,726,000 after acquiring an additional 272 shares in the last quarter. Arlington Partners LLC lifted its stake in Novo Nordisk A/S by 4.4% in the second quarter. Arlington Partners LLC now owns 6,777 shares of the company’s stock worth $325,000 after acquiring an additional 283 shares during the period. Finally, Parkside Financial Bank & Trust lifted its stake in Novo Nordisk A/S by 13.1% in the second quarter. Parkside Financial Bank & Trust now owns 2,436 shares of the company’s stock worth $117,000 after acquiring an additional 283 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Berenberg Bank set a $47.00 price objective on Novo Nordisk A/S in a research note on Wednesday, August 12th. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Thursday, August 27th. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $64.94.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: European regulators issued positive recommendations for Novo’s hemophilia A therapy FREHEMGO (denecimig), supporting a potential 2026 launch and providing a new rare-disease revenue opportunity. EMA panel backs Novo Nordisk haemophilia A drug FREHEMGO
• Positive Sentiment: Sogroya received an important European recommendation for treating children with idiopathic short stature. Clinical data showed weekly treatment performed comparably with daily growth-hormone therapy, expanding the drug’s potential market. Sogroya wins EU recommendation
• Positive Sentiment: Novo agreed to collaborate with Orbis Medicines on oral cardiometabolic drugs in a deal worth up to $1.4 billion. The partnership could help Novo develop oral alternatives to injectable therapies and diversify its obesity and diabetes pipeline. Novo and Orbis sign oral-drug deal
• Positive Sentiment: An expanded partnership with Anthropic will use artificial intelligence to accelerate drug discovery and development. Investors view the initiative as a potential way to improve research productivity, though financial benefits are longer term. Novo expands AI push with Anthropic
• Positive Sentiment: Novo confirmed stable Ozempic supply in Canada amid elevated semaglutide demand, reducing near-term availability concerns in an important market. Novo confirms stable Ozempic supply in Canada
• Negative Sentiment: Novo halted two additional ziltivekimab cardiovascular trials after a late-stage study failed to reduce major adverse cardiovascular events. The setback weighs on efforts to diversify beyond the company’s core GLP-1 franchise. Novo halts two heart-drug trials
• Negative Sentiment: Analysts continue to cite intensifying competition from Eli Lilly, semaglutide-related risks and recent share-price weakness. The Anthropic deal also has no disclosed financial terms or productivity targets, limiting its immediate earnings impact. Novo stock outlook amid competition

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida’s 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida’s 18th Congressional District. He declared candidacy for the 2026 election.

Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012.

Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin’s career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.